ProImmune Introduces ProSentium™ a Unique Peptide Sequence Database to Investigate T Cell Immune System

ProImmune Introduces ProSentium™
a Unique Peptide Sequence Database to Investigate T Cell Immune System

New service and extensive data collection covers vast range of antigens with high disease relevance

Oxford,UK, 14 April 2015
– ProImmune, a leader in services for understanding and managing
adaptive immune responses, announced today the introduction of a new
antigen database service called ProSentium™, based on
in vitro
assay results using sequencing mass spectrometry. ProSentium data
can show the precise peptide sequences from proteins of interest
visible to the body’s own T cell immune system. The data
collection covers many high value therapeutic targets and areas including the
majority of licensed replacement factor proteins, including clotting
factors, replacement enzymes, spanning development areas including
oncology, cardiovascular, CNS, immunology, gastroenterology and many
orphan diseases.

Under an exclusive or non-exclusive license, the bespoke database service
investigates and reports peptide hits against the ProSentium
database for a customer’s specific protein or protein family of
interest. Results are reported as overlapping nested peptide sets
and provide statistically relevant antigen sequence data that can be
used to further inform drug development decisions.

Nikolai Schwabe,
CEO of ProImmune commented: “ProSentium supports pivotal decision
making in drug design and development with the physical evidence
required for game changing approaches that target or interact with
the immune system. Through our service offering, we are delighted
that we can offer this ground-breaking resource to researchers so
they can better understand the body’s immune response and bring new
therapies to patients. ”

T cells play a
critical role in all immune responses, including in fighting
infections, cancer and in autoimmunity and in unwanted drug
reactions. To understand T cell responses, it is crucial to
understand the specific peptide antigens that the immune system
recognizes and are presented on the cell surface of both normal and
diseased cells. ProSentium data can be readily analyzed and
reported, and is fully compatible with ProImmune’s in vitro
assay services which can be combined to help investigators gain a
more complete understanding of relevant immune responses at a
molecular level.

For more information on ProSentium please visit:
www.proimmune.com, email
enquiries@www.proimmune.com
, or call +1 888 505 7765 in the United States or +44 870 042 7279 inother countries.

More on ProSentium™

Notes to Editors:

About ProImmune –

www.proimmune.com

ProImmune’s mission is
to be a partner of choice for understanding and managing immune
responses. It does this by offering unique solutions for preclinical
and clinical immunology research, including a comprehensive and
integrated antigen characterization and immunogenicity testing
platform, and products and services for tracking specific immune
responses. ProImmune is committed to helping researcher’s achieve
success through product innovation, responsive service and focused
application support, saving time and money, and reducing risk.

For more information, please contact

At ProImmune:

Jeremy Fry

Tel: +44 (0) 870 042 7279

Email:
enquiries@www.proimmune.com

Media enquiries:

Sarah Jeffery

Zyme Communications Ltd

Tel: +44 (0) 7771 730 919

Email:
sarah.jeffery@zymecommunications.com

USA & Canada, Toll Free: +1 888 505 7765

All other countries: +44 (0)870 042 7279